Remove Botox Remove Medicine Remove Sales
article thumbnail

Top 10 Pharma and Biotech M&As in the Past Decade

XTalks

While the deal required regulatory divestitures, including the sale of Otezla (apremilast) to Amgen for $13.4 This strategic move transformed Actavis into one of the largest pharma companies globally, with a strong presence across branded, generic and over-the-counter (OTC) medicines.

Marketing 104
article thumbnail

NICE backs Lilly’s Emgality for migraine, adding pressure on Novartis

pharmaphorum

NICE has backed Emgality (galcanezumab) as a once-monthly injection to prevent migraine attacks in people with episodic or chronic migraine who suffer at least four days with a migraine headache per month, and who have tried at least three prior preventative medicines.

Sales 96
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NICE backs Lilly’s Emgality for migraine, adding pressure on Novartis

pharmaphorum

NICE has backed Emgality (galcanezumab) as a once-monthly injection to prevent migraine attacks in people with episodic or chronic migraine who suffer at least four days with a migraine headache per month, and who have tried at least three prior preventative medicines.

Sales 94
article thumbnail

Top 20 Best-Selling Neurology Drugs to Watch in 2024

XTalks

In this blog, we highlight the top 20 best-selling neurology drugs to watch in 2024, based on 2023 sales statistics. We discuss each drug’s approved uses, sales performance and why they’ve become essential in the neurology space. Related: Top 30 Drugs to Watch in 2024: Insights from 2023 Sales Data 1.

article thumbnail

AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results

The Pharma Data

– Full-Year Global Net Revenues from the Aesthetics Portfolio Were $2.590 Billion; Global Botox Cosmetic Net Revenues Were $1.112 Billion. – Full-Year Global Net Revenues from the Neuroscience Portfolio Were $3.496 Billion; Global Botox Therapeutic Net Revenues Were $1.387 Billion; Global Vraylar Net Revenues Were $951 Million.

Botox 52
article thumbnail

AbbVie Reports Second-Quarter 2021 Financial Results

The Pharma Data

AbbVie delivered another strong quarter and our business continues to perform extremely well across the portfolio, with AbbVie’s new immunology assets contributing more than $1 billion of combined sales in the quarter,” said Richard A. Global Botox Therapeutic net revenues were $603 million, an increase of over 100.0

Botox 52
article thumbnail

Latest ABPI code breaches reveal the risk of ‘likes’ on LinkedIn

pharmaphorum

Complaints upheld by the Prescription Medicines Code of Practice Authority (PMCPA) include two against AZ and Allergan – now part of AbbVie – related to promotion of medicines on social media sites, including LinkedIn. Britannia, GSK and Sanofi were upbraided for other breaches of the code unrelated to social media.

Botox 64